An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Relapsed Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
Latest Information Update: 03 Apr 2023
At a glance
- Drugs Anti CD22 chimeric antigen receptor T cell therapy-Hebei Senlang Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hebei Senlang Biotechnology
- 23 Nov 2020 New trial record